Merck Posts 4Q Revenue Growth on Oncology, Vaccine Gains
February 04 2021 - 7:36AM
Dow Jones News
By Matt Grossman
Merck & Co. Inc. on Thursday logged an adjusted profit in
the latest quarter as growth in its oncology and vaccine sales
drove higher revenue despite the negative effect of the Covid-19
pandemic on sales.
The Kenilworth, N.J.-based pharmaceutical company logged a
fourth-quarter loss of 83 cents a share, compared with earnings of
92 cents a share in the year-ago quarter. The company's net loss
was $2.09 billion, a swing from a profit of $2.36 billion in the
prior year's fourth quarter.
On an adjusted basis, Merck posted a profit of $1.32 a share.
Analysts surveyed by FactSet were forecasting adjusted earnings of
$1.38 a share.
Merck's revenue was $12.51 billion, up 5% from $11.87 billion in
the fourth quarter of 2019. Analysts were expecting revenue of
$12.67 billion.
The pandemic negatively impacted Merck's pharmaceutical revenue
by $400 million in the latest quarter, the company said. Social
distancing and reduced health-care visits particularly affected
sales of vaccines for other diseases, according to the company. The
full-year impact to Merck's revenue from the pandemic was about
$2.5 billion, the company said.
Overall, pharmaceutical revenue in the quarter grew 8% to $11.4
billion, with growth driven primarily by oncology and vaccine
sales.
Animal-health sales grew 4% to $1.2 billion.
The company forecast full-year revenue for 2021 of $51.8 billion
to $53.8 billion and adjusted earnings of $6.48 to $6.68 a
share.
Analysts had been forecasting revenue of $51.66 million and an
adjusted profit of $6.30 a share.
Merck said Thursday that Chief Executive Kenneth C. Frazier will
retire at the end of June. He will be succeeded by Robert M. Davis,
the current chief financial officer.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
February 04, 2021 07:21 ET (12:21 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024